Solmate board re-elected as RBCH challenges May RDO and poison pill
Solmate Infrastructure (Nasdaq: SLMT) re-elected all five directors at its 2026 AGM on June 26 in Abu Dhabi, even after RBCH Ltd. filed a derivative lawsuit on June 22. The vote saw 71.49% of shares represented, with director support ranging from 62% to nearly 70%.
The fight centers on alleged governance failures tied to a May 2026 registered direct offering (RDO). RBCH claims two directors, Ron Sade and Keren Maimon, acquired 2.298 million shares at $4.97 each through the RDO. RBCH alleges the shares were valued at about 34% of Solmate’s net asset value and caused roughly $18 million in dilution to other shareholders.
Institutional Shareholder Services (ISS) recommended shareholders vote “no” on re-electing every director, citing concerns including board independence and the adoption of a poison pill arrangement in April 2026. ISS issued its recommendation on June 16, with shareholders given about ten days to consider it.
For traders, Solmate board re-elected does not resolve the underlying dispute. The derivative lawsuit remains active, and RBCH still holds over a 10% stake. The $18 million dilution figure is the key potential catalyst: if discovery supports insider-favoring structuring, legal and financial fallout could escalate. If the board’s claim that the suit is retaliatory holds, RBCH may face reduced leverage in future negotiations.
Bottom line: this is a governance headline for SLMT investors, with possible medium-term legal/valuation risk depending on lawsuit developments.
Neutral
The story is primarily a governance and litigation overhang for SLMT rather than a direct operational or token-demand catalyst. A board sweep following an ISS “vote no” recommendation can create short-term sentiment swings, but the market impact depends on lawsuit discovery outcomes. Similar governance disputes often resolve in waves: initial uncertainty after votes, followed by sharper repricing once court filings, settlements, or evidentiary findings clarify dilution, fiduciary-duty claims, or related-party transaction structure. In the near term, traders may price in headline risk and widen risk premia for SLMT; in the longer term, outcomes from the derivative lawsuit could either reinforce a “no merit/retaliation” narrative (neutralizing the discount) or trigger financial and legal costs that weigh on equity value. Overall, without evidence of immediate liquidity or business disruption, the expected effect on crypto-adjacent markets is best classified as neutral.